These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 30614531)

  • 1. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
    Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
    Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative Hyperselection of Patients With
    Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in
    Modest DP; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; Fischer von Weikersthal L; Caca K; Kretzschmar A; Goekkurt E; Haas S; Kurreck A; Stahler A; Held S; Jarosch A; Horst D; Reinacher-Schick A; Kasper S; Heinemann V; Stintzing S; Trarbach T
    J Clin Oncol; 2022 Jan; 40(1):72-82. PubMed ID: 34533973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
    Nagata N; Mishima H; Kurosawa S; Oba K; Sakamoto J
    Clin Colorectal Cancer; 2017 Jun; 16(2):154-157.e1. PubMed ID: 28284575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
    McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
    Popov I; Milicević M; Radosević-Jelić Lj
    Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
    Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
    Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
    Manca P; Corallo S; Randon G; Lonardi S; Cremolini C; Rimassa L; Bergamo F; Antoniotti C; Smiroldo V; Zaniboni A; Murialdo R; Tampellini M; Tomasello G; Clavarezza M; Racca P; Antista M; Raimondi A; Prisciandaro M; Pagani F; Palermo F; Greco FG; Vaiani M; Di Bartolomeo M; de Braud F; Calareso G; Morano F; Pietrantonio F
    Eur J Cancer; 2021 Feb; 144():31-40. PubMed ID: 33321462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
    Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
    BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.